Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis

Lung, Respiratory and Thoracic Cancer

Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis

Lung Cancer

Zhang Y, Zhao J, Ma Z, Yi J, Yuan Y, Lang L, Zhang C, Zhu M, Zhang Y

doi: 10.1016/j.lungcan.2025.108700

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Eur J Cancer

Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, Aguinarte L, Schulte H, Serve H, Oellerich T, Sebastian M, Althoff FC

doi: 10.1016/j.ejca.2025.115266

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Lung, Respiratory and Thoracic Cancer

Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis

Lung Cancer

Gawli CS, Patil BR, Nagpure NR, Patil CR, Kumar A, Patel HM

doi: 10.1016/j.lungcan.2025.108629

Lung, Respiratory and Thoracic Cancer

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1

Lung Cancer

Murata D, Azuma K, Murotani K, Ito K, Nomizo T, Yamada K, Imabayashi T, Iwanaga K, Chibana K, Ota T, Nishii Y, Nakao A, Okada A, Hamai K, Tanimura K, Yoshimine K, Tamura Y, Takaki R, Goto Y, Hibino M, Oba T, Sumi T, Kaneda H, Nishioka N, Yamada T, Takayama K

doi: 10.1016/j.lungcan.2025.108772

Lung, Respiratory and Thoracic Cancer

Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data

Lung Cancer

Gemelli M, Cortinovis D, Carola G, Moretti L, Piazza F, Calza S, Ricotta R, Grisanti S, Rota M

doi: 10.1016/j.lungcan.2025.108621

Further Publications

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis

JAMA Oncol

Saleem N, Wang J, Rejuso A, Teixeira-Pinto A, Stephens JH, Wilson A, Kieu A, Gately RP, Boroumand F, Chung E, Bonevski B, Carlino MS, Carroll R, Lim WH, Craig JC, Murakami N, Wong G

doi: 10.1001/jamaoncol.2025.2374

Lung, Respiratory and Thoracic Cancer

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Clin Cancer Res

Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A, Rizvi H, Wang X, Jeng M, Egger JV, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Clark P, Nishino M, Johnson BE, Hellmann M, Schoenfeld AJ, Awad MM

doi: 10.1158/1078-0432.CCR-24-2990

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis

Lung Cancer

Pan Y, Gu Q

doi: 10.1016/j.lungcan.2025.108532

Related content

Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1

Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis